Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Hamanishi, Junzo; Takeshima, Nobuhiro; Katsumata, Noriyuki; Ushijima, Kimio; Kimura, Tadashi; Takeuchi, Satoshi; Matsumoto, Koji; Ito, Kimihiko; Mandai, Masaki; Nakai, Hidekatsu; Sakuragi, Noriaki; Watari, Hidemichi; Takahashi, Nobutaka; Kato, Hidenori; Hasegawa, Kosei; Yonemori, Kan; Mizuno, Mika; Takehara, Kazuhiro; Niikura, Hitoshi; Sawasaki, Takashi; Nakao, Sari; Saito, Toshiaki; Enomoto, Takayuki; Nagase, Satoru; Suzuki, Nao; Matsumoto, Takashi; Kondo, Eiji; Sonoda, Kenzo; Aihara, Satomi; Aoki, Yoichi; Okamoto, Aikou; Takano, Hirokuni; Kobayashi, Hiroshi; Kato, Hisamori; Terai, Yoshito; Takazawa, Akira; Takahashi, Yusuke; Namba, Yoshinobu; Aoki, Daisuke; Fujiwara, Keiichi; Sugiyama, Toru; Konishi, Ikuo

doi:10.1200/jco.21.00334

Public

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Published in Journal of Clinical Oncology • Sep 2, 2021

Authors:

Junzo Hamanishi

Nobuhiro Takeshima

Noriyuki Katsumata

Abstract

PURPOSE This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. MATERIALS AND METHODS Eligible patients had platinu...

Subject

Medicine

Nivolumab

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!